Artificial Pancreas Device System (APDS) Market, By Technology (Threshold Suspended Device Systems, Treat to Range/Control to Range (TTR/CTR), and Treat to Target/ Control to Target (TTR/CTT)), by Distribution Channel (Hospitals & Clinics, Online Channels

Artificial Pancreas Device System (APDS) Market, By Technology (Threshold Suspended Device Systems, Treat to Range/Control to Range (TTR/CTR), and Treat to Target/ Control to Target (TTR/CTT)), by Distribution Channel (Hospitals & Clinics, Online Channels, and Retail Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Type 1 diabetes patients require multiple doses of insulin in a day. Advancements in research and technology has led to commercialization of easy-to-use insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems.
Moreover, these systems offer self-administration of insulin. Artificial pancreas system automatically detects glucose level in patient’s blood or plasma, and accordingly administers necessary dosage of insulin. For instance, Medtronic's MiniMed 670G is one such wearable artificial pancreas that automatically monitors glucose levels, and delivers insulin through an insulin pump attached to the device. The artificial pancreas technology includes a transmitter, sensor, and insulin pump. This helps in continuous monitoring of insulin levels in body and manages diabetes at ease.
Market Dynamics
Continuous research and development of novel artificial pancreas device systems is expected to support the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, in May 2021 Beta Bionics, Inc. and Zealand Pharma started an in-home trial of iLet Bionic Pancreas system, a dual-hormone pump system designed to automatically deliver insulin and dasiglucagon – an experimental form of glucagon designed by Zealand Pharma to be stable in liquid form- based on blood sugar readings from a continuous glucose monitor (CGM).
High prevalence of diabetes type 1 is expected to rise demand for its novel monitoring systems and drive the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, according to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. Furthermore, according to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S.
Key features of the study:
This report provides in-depth analysis of global artificial pancreas device system (APDS) market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global artificial pancreas device system (APDS) market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Medtronic Plc., Medtrum Technologies Inc., Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Inc., Bigfoot Biomedical, Insulet Corporation, Pancreum, Inc., TypeZero Technologies, Inc., DreaMed Diabetes Ltd, and Inreda Diabetic BV
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global artificial pancreas device system (APDS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global artificial pancreas device system (APDS) market
Detailed Segmentation:
Global Artificial Pancreas Device System (APDS) Market, By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
Global Artificial Pancreas Device System (APDS) Market, By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
Global Artificial Pancreas Device System (APDS) Market, By Region:
North America
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country:
U.S.
Canada
Europe
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country:
GCC
Israel
Rest of Middle East
Africa
By Technology :
Threshold Suspended Device Systems
Treat to Range/Control to Range (TTR/CTR)
Treat to Target/ Control to Target (TTR/CTT)
By Distribution Channel:
Hospital & Clinics
Retail Channels
Online Channels
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Medtronic Plc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Medtrum Technologies Inc.
Tandem Diabetes Care, Inc.
Johnson & Johnson
Beta Bionics, Inc.
Bigfoot Biomedical
Insulet Corporation
Pancreum, Inc.
TypeZero Technologies, Inc.
DreaMed Diabetes Ltd
Inreda Diabetic BV
“*” marked represents similar segmentation in other categories in the respective section.